Syndax Pharmaceuticals Inc (SNDX) — Cash Flow-to-Debt Ratio
Syndax Pharmaceuticals Inc (SNDX) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2026, meaning its operating cash flow of $-50.34 Million could theoretically repay 0% of its total liabilities ($431.05 Million) in one year. See Syndax Pharmaceuticals Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Syndax Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Syndax Pharmaceuticals Inc across 15 annual periods. Also explore SNDX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Syndax Pharmaceuticals Inc (2011–2025)
Year-by-year debt coverage analysis for Syndax Pharmaceuticals Inc. For market capitalisation and broader financial context, see SNDX stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.69x | $-322.98 Million | $465.08 Million | ▼ -10.3% |
| 2024 | -0.63x | $-274.90 Million | $436.69 Million | ▲ +77.0% |
| 2023 | -2.74x | $-160.60 Million | $58.68 Million | ▲ +39.0% |
| 2022 | -4.49x | $-133.68 Million | $29.79 Million | ▼ -736.1% |
| 2021 | 0.71x | $29.13 Million | $41.29 Million | ▲ +147.9% |
| 2020 | -1.47x | $-71.26 Million | $48.42 Million | ▲ +7.2% |
| 2019 | -1.59x | $-50.61 Million | $31.93 Million | ▲ +28.5% |
| 2018 | -2.22x | $-68.53 Million | $30.89 Million | ▼ -53.9% |
| 2017 | -1.44x | $-47.37 Million | $32.87 Million | ▼ -2.0% |
| 2016 | -1.41x | $-35.16 Million | $24.87 Million | ▼ -1250.8% |
| 2015 | -0.10x | $-2.43 Million | $23.20 Million | ▲ +86.5% |
| 2014 | -0.78x | $-14.39 Million | $18.53 Million | ▲ +44.5% |
| 2013 | -1.40x | $-7.29 Million | $5.21 Million | ▼ -364.3% |
| 2012 | -0.30x | $-9.28 Million | $30.80 Million | ▲ +28.3% |
| 2011 | -0.42x | $-10.02 Million | $23.84 Million | — |